FDA 公布 Glenmark 印度果阿制剂厂 483 检查报告,共列 6 项观察
FDA 483:格兰马克制药,点名清洁、记录与色谱权限!
FDA 公布对 Glenmark Pharmaceuticals 印度果阿邦 Colvale 制剂厂(FEI 3004672766)的 483,2026 年 6 月 22 日至 30 日检查后共列 6 项观察。
483 逐项列出清洁时间、审计追踪与色谱权限的观察,可对照清洁验证与数据完整性检查的取证方式。
近日,FDA公布了 Glenmark Pharmaceuticals Limited 位于印度果阿邦 Colvale 工业区的制剂厂(Plot No. S-7,FEI 3004672766)的483检查报告,列6项观察:
第1项最刺眼。按清洁程序 SOP CM/PD002,Type A 清洁(同品种连续生产期间)与 Type B 清洁(换线时)的耗时分被记录为1分钟、5分钟、8分钟、11分钟、14分钟。Type B 要求湿擦、并目视检查地面四角、边缘与设备下方,记录照样写5分钟完成。企业从未为这两类清洁设定最低时间,更没有验证过这个时间够不够走完全部步骤。
消毒剂那一半也是空的:2023年的方案与2024年的总结报告,缺阳性对照、缺清洁前微生物计数、缺挑战试验与未处理对照面;接受标准直接照搬 Grade D 日常环境监测限值,也没按自家2016年验证(VP/MM/QC/206)要求的对数下降来判定;而且从未规定过任何消毒剂的最低接触时间。
其余五项:片剂设备没有审计追踪、参数调整无上限;高风险原料只做混合样、未逐容器做鉴别;压差只在生产时记录、无报警,两处厂房相距 (b)(4),交叉污染风险评估不完整;年度产品质量回顾漏掉投诉(一份写0起、实际11起);Empower 权限允许在改方法时预览峰面积而不保存色谱图。
翻译如下:
图1 FDA 483 原件第1页(FEI 3004672766,共11页)
Inspection Details
检查基本信息
Firm / 企业
Glenmark Pharmaceuticals Limited 格兰马克制药
Address / 地址
Plot No. S-7, Colvale Industrial Estate(Colvale 工业区 S-7 地块)
City / 城市
Colvale, Bardez, Goa 403 513, India(印度果阿邦巴尔德斯县科尔瓦莱,邮编403 513)
FEI Number / FEI 号
3004672766
Dates of Inspection / 检查日期
2026年6月22日–6月30日(原件写作 06/22-30/2026)
Type Establishment Inspected / 受检设施类型
Drug Manufacturer(药品生产商)
Issued To / 收件人
Ganpat Sonyabapu Pote, Vice President Operation & Site Head(甘帕特·索尼亚马布·波特,运营副总裁兼厂区负责人)
Issuing Office / 签发部门
12420 Parklawn, Room 2032, Rockville, MD 20857;CDER-OC-OMQ-International483response@fda.hhs.gov(FDA 药品评价与研究中心国际检查部门)
Issued / 签发
2026年6月30日 检查员:Lisa L. Flores;Rafeeg A. Habeeb;Jared P. Stevens
说明:原件六项观察的标题均为叙述句,不引条款号;本稿标题后的条款号系编者按条文内容比对所加,见文末译注①。
OBSERVATION 1
观察1:清洁与消毒的间隔、时间不适当(211.67(a)(b))
Equipment and utensils are not cleaned or sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
设备与器具未按适当的间隔清洁或消毒,以防止可能改变药品安全性、鉴别、含量、质量或纯度的污染。
Specifically,
具体而言,
A. Inadequate Cleaning Procedures - Insufficient Time Allocation
A. 清洁程序不充分——时间分配不足
Your firm's written cleaning procedure, SOP CM/PD002 "Cleaning and Sanitization of Production Areas, Other than Production Areas, Wash Areas and Drain Points", establishes requirements for Type A cleaning and Type B cleaning of (b)(4) manufacturing rooms. Type A cleaning is performed during continued production of the same product, while Type B cleaning is performed during product changeover to prevent cross-contamination between different drug products.
贵公司的书面清洁程序 SOP CM/PD002《生产区、非生产区、清洗区与排水点的清洁与消毒》,规定了 (b)(4) 生产房间 Type A 清洁与 Type B 清洁的要求。Type A 清洁在同一产品连续生产期间进行;Type B 清洁在产品换线时进行,以防止不同药品之间发生交叉污染。
Review of cleaning records for (b)(4) rooms revealed documented cleaning times that are physically insufficient to complete all required procedural steps.
对 (b)(4) 个房间清洁记录的复核显示,所记录的清洁时间在物理上不足以完成全部规定的程序步骤。
1. Type A Cleaning – Examples of Inadequate Times
1. Type A 清洁——时间不足的实例
Type A cleaning requires sequential steps for (b)(4) (b)(4) operations (b)(4). The following examples demonstrate that documented cleaning times do not allow completion of all required steps:
Type A 清洁须依次完成 (b)(4) (b)(4) 操作 (b)(4)。以下实例说明,所记录的清洁时间不足以完成全部规定步骤:
March 17, 2026: (b)(4) Room (b)(4) (1 minute) – documented as completing (b)(4)
2026年3月17日:(b)(4) 房间 (b)(4),记录为1分钟——记录称已完成 (b)(4)
August 18, 2025: (b)(4) Room (b)(4) (5 minutes) – documented as completing (b)(4)
2025年8月18日:(b)(4) 房间 (b)(4),记录为5分钟——记录称已完成 (b)(4)
March 18, 2026: (b)(4) Room (b)(4) (5 minutes) – documented as completing (b)(4)
2026年3月18日:(b)(4) 房间 (b)(4),记录为5分钟——记录称已完成 (b)(4)
2. Type B Cleaning – Examples of Inadequate Times
2. Type B 清洁——时间不足的实例
Type B cleaning is performed during product changeover and requires more extensive cleaning than Type A, including wet cleaning (using (b)(4) (b)(4)) and visual inspection of cleaned areas to confirm effectiveness. Review of Type B cleaning records revealed that documented times are insufficient to complete all required steps:
Type B 清洁在产品换线时进行,清洁范围比 Type A 更大,包括湿擦(使用 (b)(4) (b)(4))以及对已清洁区域做目视检查以确认有效性。对 Type B 清洁记录的复核显示,所记录的时间不足以完成全部规定步骤:
April 22, 2026: (b)(4) (Unit (b)(4)), Room (b)(4) (14 minutes) – documented as completing wet cleaning of (b)(4) (b)(4) operations, and visual inspection of floor corners, edges, and under-equipment areas
2026年4月22日:(b)(4)((b)(4) 单元),房间 (b)(4),记录为14分钟——记录称已完成对 (b)(4) 的湿擦、(b)(4) 操作,以及地面四角、边缘与设备下方区域的目视检查
January 16, 2025: (b)(4) Facility (Unit (b)(4)) Room (b)(4) (b)(4) (8 minutes) – documented as completing wet cleaning of (b)(4) operations, and required visual inspection.
2025年1月16日:(b)(4) 设施((b)(4) 单元)房间 (b)(4) (b)(4),记录为8分钟——记录称已完成 (b)(4) 的湿擦、相关操作,以及规定的目视检查。
February 13, 2025: (b)(4) Facility (Unit (b)(4)) Room (b)(4) (b)(4) (5 minutes) – documented as completing wet cleaning of (b)(4) operations, and required visual inspection.
2025年2月13日:(b)(4) 设施((b)(4) 单元)房间 (b)(4) (b)(4),记录为5分钟——记录称已完成 (b)(4) 的湿擦、相关操作,以及规定的目视检查。
February 21, 2025 (b)(4) (Unit (b)(4)) Room (b)(4) (b)(4) (11 minutes) – documented as completing wet cleaning of (b)(4) operations, and required visual inspection.
2025年2月21日 (b)(4)((b)(4) 单元)房间 (b)(4) (b)(4),记录为11分钟——记录称已完成 (b)(4) 的湿擦、相关操作,以及规定的目视检查。
Your firm has not established a minimum or validated cleaning time for Type A and Type B cubicle cleaning. Without scientifically justified time requirements, there is no basis to determine whether documented cleaning times are adequate to complete all required procedural steps.
贵公司未为 Type A 与 Type B 的洁净间清洁设定最低时间,也未做验证。没有经科学论证的时间要求,就无从判断所记录的清洁时间是否足以完成全部规定的程序步骤。
B. Lack of Validated Contact Time for Disinfectants
B. 消毒剂接触时间未经验证
1. Protocol MSP/QC/2023/005/00/CMPD002 (effective 13/02/2023) and Summary Report MSR/QC/2023/005/00/CMPD002 (dated 01/06/2024) were conducted to demonstrate the effectiveness of the disinfectants used in the sanitization procedure. However, the study design cannot demonstrate disinfectant efficacy because it lacks the following critical elements:
1. 方案 MSP/QC/2023/005/00/CMPD002(2023年2月13日生效)与总结报告 MSR/QC/2023/005/00/CMPD002(2024年6月1日)旨在证明消毒程序中使用的消毒剂有效。但该研究设计无法证明消毒剂效力,因为它缺少以下关键要素:
Positive controls
阳性对照
Pre-cleaning microbial counts
清洁前的微生物计数
Deliberate microbial challenge
有意的微生物挑战
Untreated control surfaces
未处理的对照表面
Inadequate Acceptance Criteria
接受标准不适当
2. The study's acceptance criteria of "Total aerobic Microbial count: NMT (b)(4) cfu/plate" fails to demonstrate disinfectant efficacy for two reasons:
2. 该研究的接受标准为“总需氧微生物计数:不超过 (b)(4) cfu/皿”,无法证明消毒剂效力,理由有二:
The acceptance criteria is identical to routine environmental monitoring limits for Grade D areas and therefore does not demonstrate disinfectant efficacy. The acceptance criteria measures surface cleanliness, meaning there is no scientific basis to distinguish between effective disinfection and low baseline contamination.
该接受标准与 Grade D 区日常环境监测限值完全相同,因此不能证明消毒剂效力。这一标准测的是表面洁净度,意味着无法从科学上区分“消毒有效”与“基线污染本来就低”。
There is no scientific justification for the absence of a log reduction calculation requirement. Your firm's own 2016 validation (Protocol VP/MM/QC/206) established acceptance criteria of ≥(b)(4)% reduction for vegetative organisms and ≥(b)(4)% reduction for spores, yet these standards were not applied in Protocol MSP/QC/2023/005/00/CMPD002 (effective 13/02/2023) and Summary Report MSR/QC/2023/005/00/CMPD002 (dated 01/06/2024).
未要求做对数下降计算,且无科学理由。贵公司自家2016年的验证(方案 VP/MM/QC/206)曾设定接受标准:繁殖体下降 ≥(b)(4)%、芽孢下降 ≥(b)(4)%;但这两项标准并未用于方案 MSP/QC/2023/005/00/CMPD002(2023年2月13日生效)与总结报告 MSR/QC/2023/005/00/CMPD002(2024年6月1日)。
C. Absence of Validated Contact Time
C. 未验证接触时间
Your firm has not established or validated a minimum contact time for any of the (b)(4) disinfectants used (b)(4). The absence of specified contact times, combined with the inadequate total cleaning times documented above, could indicate that effective sanitization is not being achieved. In the documented cleaning records, if all procedural steps are completed within the allocated time, there is no remaining time for disinfectant to remain in contact with floor surfaces before the room is returned to use.
贵公司未为所使用的 (b)(4) 种消毒剂中的任何一种设定或验证最低接触时间 (b)(4)。既未规定接触时间,加上前述总清洁时间本就不足,可能意味着消毒并未真正达到效果。在已记录的清洁记录中,如果全部程序步骤都在所分配的时间内做完,就没有剩余时间让消毒剂在地面停留、接触,房间便已恢复使用。
OBSERVATION 2
观察2:计算机化系统控制不足(211.68(b))
Appropriate controls were not exercised over computer or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
未对计算机或相关系统实施适当控制,以确保主生产与控制记录或其他记录的变更仅由经授权人员实施。
Specifically,
具体而言,
A. (b)(4) machines—the (b)(4) (b)(4) are all documented as having no electronic data storage or audit trail capability. These machines are used to manufacture multiple tablet products for distribution in the United States, including (b)(4).
A. (b)(4) 机器——(b)(4) (b)(4) 均记录为不具备电子数据存储或审计追踪功能。这些机器用于生产多个销往美国的片剂产品,包括 (b)(4)。
1. The (b)(4) machines lack electronic data storage and audit trail functionality. While printed reports are generated and subsequently scanned for archival, the original electronic data on the machines themselves cannot be retrieved, trended, or audited. This prevents verification of:
1. 这些 (b)(4) 机器缺少电子数据存储与审计追踪功能。虽然会生成打印报告、随后扫描归档,但机器本身的原始电子数据无法调取、无法做趋势分析、也无法审计。这导致以下各项无法核实:
▪ a. Authorization status of changes at the time they were made
▪ a. 变更发生时,其授权状态如何
▪ b. Detection of unauthorized modifications to data other than process parameters
▪ b. 除工艺参数之外,数据是否被未经授权修改
▪ c. Systematic trending of parameter drift or equipment performance degradation
▪ c. 参数漂移或设备性能劣化的系统性趋势
2. There is no documented procedure establishing acceptable limits on the number or magnitude of parameter adjustments an operator may make during a single batch run within the validated range. An operator may make unlimited corrections to (b)(4) or other parameters without documented justification, and there is no mechanism to detect whether such frequent adjustments indicate process instability or equipment drift.
2. 没有书面程序规定:在单批生产、且处于已验证范围内时,操作人员可做参数调整的次数或幅度上限。操作人员可以不受限制地修正 (b)(4) 或其他参数,且无需书面说明理由;也没有机制去判断这种频繁调整是否意味着工艺不稳定或设备漂移。
3. While non-critical alarms are logged in batch records and a Work Request Memo (WRM) system exists to document equipment issues requiring engineering intervention, there is no documented procedure establishing threshold criteria (frequency or severity triggers) that define when non-critical alarms require investigation and escalation beyond routine maintenance.
3. 非关键报警虽会记入批记录,也有工程申请单(WRM)系统记录需工程介入的设备问题,但没有书面程序规定阈值标准(频次或严重度触发条件),用以界定非关键报警何时需要跳出日常维护、进入调查与上报。
B. (b)(4) machines—the (b)(4) used to manufacture multiple tablet products for distribution in the United States, including (b)(4) (b)(4) are (b)(4). Although these machines are equipped with electronic data storage and backup capability, appropriate controls are not exercised to assure that changes to process parameters are instituted only by authorized personnel, and procedures do not establish monitoring and investigation requirements for equipment "Non-Critical" alarms and parameter deviations.
B. (b)(4) 机器——用于生产多个销往美国片剂产品(包括 (b)(4))的 (b)(4) 为 (b)(4)。这些机器虽具备电子数据存储与备份能力,但未实施适当控制以确保工艺参数的变更仅由经授权人员实施;程序也未规定对设备“非关键”报警与参数偏差的监测与调查要求。
Specifically:
具体而言:
1. While the electronic audit trail captures date, time, personnel identity, old value, and new value of parameter changes, your procedures do not establish requirements to review the audit trail for: the sequence and frequency of parameter changes during a batch, whether changes were made for documented reasons, whether the pattern of changes indicates process instability or equipment drift, or whether changes were appropriate given the product and process stage. The audit trail is reviewed only for compliance with specification limits, not for assessment of the adequacy or appropriateness of the changes themselves.
1. 电子审计追踪虽记录了参数变更的日期、时间、人员身份、旧值与新值,但贵公司的程序未规定应就以下各项复核审计追踪:一批生产中参数变更的顺序与频次;变更是否有书面理由;变更模式是否提示工艺不稳定或设备漂移;变更在产品与工艺阶段上是否恰当。审计追踪只被用来核对外观是否符合限度,而未用来评价变更本身是否充分、是否恰当。
2. Your procedures do not establish requirements to monitor the frequency or pattern of non-critical alarms, define investigation criteria or trigger points for repeated non-critical alarms that may indicate emerging equipment problems, or require documentation of non-critical alarm occurrences for trend analysis.
2. 贵公司的程序未规定:监测非关键报警的频次或模式;为反复出现的非关键报警(可能提示设备正在出现问题)设定调查标准或触发点;或要求记录非关键报警的发生情况以做趋势分析。
3. While your SOPs establish acceptance limits for process parameters and define alarm thresholds, the procedures do not establish predefined investigation criteria for parameter deviations that do not generate alarms. The SOPs do not establish predefined trigger points for investigation of parameter drift within acceptable limits or trend monitoring of parameters that remain within specification but show directional drift.
3. 贵公司的 SOP 虽为工艺参数设定了可接受限度、也定义了报警阈值,但程序未就“不触发报警的参数偏差”预设调查标准;SOP 也未就不超出可接受限度的参数漂移预设调查触发点,也未要求对仍在标准内、但呈方向性漂移的参数做趋势监测。
OBSERVATION 3
观察3:组分未按书面标准全项检验(211.84)
Each component is not tested for conformity with all written specifications for purity, strength, and quality.
每一组分未按纯度、含量与质量的全部书面标准检验其符合性。
Specifically,
具体而言,
Your firm failed to perform individual container testing, including identity testing with limits for (b)(4) (NMT (b)(4) %), on each individual container of each shipment of each lot of high-risk drug components prior to their use in manufacturing of drug products distributed to the United States market. Your procedure for sample testing, Sampling, Testing and Release of Raw Materials, SOP 19/QC006, allows analysis of (b)(4) samples.
对高风险药品组分,贵公司未在其用于生产销往美国市场的药品之前,对每批、每次到货的每个容器逐一做容器检验,包括带限度要求的鉴别检验((b)(4),不超过 (b)(4) %)。贵公司的取样检验程序《原料的取样、检验与放行》SOP 19/QC006 允许只分析 (b)(4) 个样品。
The high-risk raw materials tested using (b)(4) samples include:
使用 (b)(4) 个样品检验的高风险原料包括:
Raw Material | Most recent Glenmark material batch # |
|---|---|
(b)(4)(原件此表表体整块脱敏,行数与物料名称不可辨) | (b)(4) |
These raw materials have been used to manufacture commercial product intended for the US market including (b)(4).
这些原料已被用于生产拟销往美国市场的商业产品,包括 (b)(4)。
OBSERVATION 4
观察4:防污染与防混淆的控制系统不充分(211.42(c))
Control systems for the firm's operations are not adequate to prevent contamination or mix-ups.
贵公司运行的控制系统不足以防止污染或混淆。
Specifically,
具体而言,
A. Differential pressure in the manufacturing areas of the (b)(4) facility (Unit (b)(4)) is not adequately monitored and recorded, and no alarm system in place to detect differential pressure excursions. A review of the Batch Production Record (BPR) for Batch (b)(4) (b)(4) USP (b)(4) mcg), confirmed that the differential pressure is recorded only during active batch production, approximately (b)(4) with no continuous monitoring or alarm system to ensure pressure differentials are maintained. Your firm manufactures (b)(4) drug products approved for the U.S. market in Unit (b)(4). Approximately (b)(4) distinct batches—including (b)(4) (b)(4)—were shipped to the U.S. between January 2023 and June 2026. Your firm also manufactures (b)(4) tablets in the same facility as (b)(4) products and these (b)(4) tablets are (b)(4) packaged with (b)(4) tablets for at least (b)(4) commercial products marketed in the U.S. All these approximately (b)(4) batches remain within their approved expiry dates as of the date of this inspection (June 30, 2026).
A. (b)(4) 设施((b)(4) 单元)生产区的压差监测与记录不充分,且没有报警系统来发现压差越界。复核批号 (b)(4)((b)(4) USP (b)(4) mcg)的批生产记录(BPR)确认:压差只在批次实际生产期间记录,约 (b)(4),既无连续监测,也无报警系统来确保压差维持。贵公司在 (b)(4) 单元生产多个获批在美上市的 (b)(4) 药品。2023年1月至2026年6月,约有 (b)(4) 个不同批次——包括 (b)(4) (b)(4)——发往美国。贵公司还在与 (b)(4) 产品同一设施内生产 (b)(4) 片剂,这些 (b)(4) 片剂与 (b)(4) 片剂被 (b)(4) 包装在一起,涉及至少 (b)(4) 个在美国上市的商业产品。截至本次检查日(2026年6月30日),这约 (b)(4) 个批次全部仍在批准的效期内。
B. Although a risk assessment with containment study was done in 2023 and 2025, your firm has not conducted a comprehensive risk assessment prior to this inspection on June 22, 2026, to evaluate the potential for cross-contamination between the (b)(4) manufacturing facility (Unit (b)(4)) and the (b)(4) facility (Unit (b)(4)). The Units are located approximately (b)(4) away from each other. For example, your firm has not performed a scientific evaluation of potential (b)(4) cross-contamination between the two facilities, including an assessment of the location and (b)(4) points of the (b)(4) facility's (b)(4) systems in relation to the (b)(4) vents of the (b)(4) facility; the adequacy and a program for periodic environmental monitoring between the facilities.
B. 尽管2023年与2025年做过带遏制(containment)研究的风险评估,贵公司在本次检查(2026年6月22日)之前,未就 (b)(4) 生产设施((b)(4) 单元)与 (b)(4) 设施((b)(4) 单元)之间的潜在交叉污染做全面风险评估。两个单元相距约 (b)(4)。例如,贵公司未对两处设施之间潜在的 (b)(4) 交叉污染做科学评价,包括评估 (b)(4) 设施 (b)(4) 系统的位置与 (b)(4) 点相对于 (b)(4) 设施 (b)(4) 排风口的关系,以及两处设施之间定期环境监测的充分性与方案。
OBSERVATION 5
观察5:年度回顾未按规定执行、内容有缺陷(211.180(e))
Written procedures for annual product reviews are not followed, and the reviews are deficient in that they do not address a review of complaint records for each drug product.
年度产品回顾的书面程序未被执行;且回顾本身有缺陷——未包含对每个药品投诉记录的复核。
Specifically,
具体而言,
Your firm failed to include a review of all complaints in the Annual Product Quality Review (APQR). Your procedure, "SOP CM/QA005, Revision 17: Periodic Review of Product Quality of Drug Products," requires the compilation of market complaints for the APQR. However, complaints were not included in the APQR for the following products
贵公司未把全部投诉纳入年度产品质量回顾(APQR)。贵公司程序《SOP CM/QA005 第17版:药品质量定期回顾》要求在 APQR 中汇总市场投诉。但以下产品的 APQR 未纳入投诉:
A. Product: (b)(4) Tablets
A. 产品:(b)(4) 片
The APQR for the review period of March 25, 2024, to March 24, 2025 (APQR/25/US/007) reported zero (0) market complaints. However, a review of your firm's complaint records identified eleven (11) complaints associated with this product within the review period that were not included in the APQR including complaints for lack of efficacy and missing blisters.
回顾期为2024年3月25日至2025年3月24日的 APQR(APQR/25/US/007)报告市场投诉为零(0)起。但复核贵公司的投诉记录发现,该回顾期内与该产品相关的投诉有11起,均未纳入 APQR,其中包括疗效不足与缺泡罩的投诉。
B. Product: (b)(4) Tablets
B. 产品:(b)(4) 片
The APQR for the review period of January 19, 2024, to January 18, 2025 (APQR/25/US/001) reported one (1) market complaint. However, a review of your firm's complaint records identified a total of two (2) complaints associated with this product within the review period. Complaint number MC/I102/2024/0065 for missing blister was not included in the APQR.
回顾期为2024年1月19日至2025年1月18日的 APQR(APQR/25/US/001)报告市场投诉为1起。但复核贵公司投诉记录发现,该回顾期内与该产品相关的投诉共2起。其中缺泡罩的投诉 MC/I102/2024/0065 未纳入 APQR。
OBSERVATION 6
观察6:实验室记录未包含完整数据(211.194(a))
Laboratory records do not include complete data derived from all tests, examinations, and assays necessary to assure compliance with established specifications and standards.
实验室记录未包含为确保符合既定标准与规格所必需的全部检验、检查与测定数据。
Specifically,
具体而言,
Your analysts have been granted user privileges within the Empower software that allow them to view numerical results in the review window—including area counts of peaks—while changing processing methods, without requiring the chromatograms to be saved. This configuration allows for the potential previewing of data. While these series of controls were in place, your firm has tested over (b)(4) batches of finished drug products for assay and/or impurities by HPLC since January 2023. These products include, but are not limited to, (b)(4). Furthermore, prior to this inspection, your firm did not conduct a comprehensive risk assessment to identify and control the data integrity risks introduced by these user privilege configurations.
贵公司分析人员在 Empower 软件中被授予的用户权限,允许他们在修改处理方法时,在复核窗口查看数值结果——包括峰的峰面积——而不要求保存色谱图。这一配置使得数据可以被预先查看。在这一系列控制措施存在的情况下,自2023年1月以来,贵公司用 HPLC 检验了超过 (b)(4) 批成品的含量和/或杂质。这些产品包括但不限于 (b)(4)。此外,在本次检查之前,贵公司未做全面风险评估,以识别并控制这些用户权限配置带来的数据完整性风险。
来源:制药经理人 · mp.weixin.qq.com